BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem 2013;59:52-9. [PMID: 23034139 DOI: 10.1373/clinchem.2011.180778] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. [PMID: 30923679 DOI: 10.1016/j.bdq.2019.100087] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 47.3] [Reference Citation Analysis]
2 Jung K, Lein M. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. Biochim Biophys Acta 2014;1846:425-38. [PMID: 25220832 DOI: 10.1016/j.bbcan.2014.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
3 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 2016;26:43-51. [PMID: 26588231 DOI: 10.1097/IGC.0000000000000586] [Cited by in Crossref: 115] [Cited by in F6Publishing: 50] [Article Influence: 19.2] [Reference Citation Analysis]
5 León-Mateos L, Vieito M, Anido U, López López R, Muinelo Romay L. Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. Int J Mol Sci 2016;17:E1580. [PMID: 27657044 DOI: 10.3390/ijms17091580] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Qi Z, Zhang L, Chen Y, Ma X, Gao X, Du J, Zhang F, Cheng X, Cui W. Biological variations of seven tumor markers. Clinica Chimica Acta 2015;450:233-6. [DOI: 10.1016/j.cca.2015.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
7 Abu Hassan SO, Nielsen DL, Tuxen MK, Petersen PH, Sölétormos G. Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Sci OA 2017;3:FSO216. [PMID: 28884012 DOI: 10.4155/fsoa-2017-0023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Wood SL, Westbrook JA, Brown JE. Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment. Cancer Treat Rev 2014;40:139-52. [PMID: 23958309 DOI: 10.1016/j.ctrv.2013.07.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
9 Moritz R, Muller M, Korse C, van den Broek D, Baas P, van den Noort V, ten Hoeve J, van den Heuvel M, van Rossum H. Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot. Clinica Chimica Acta 2018;487:6-14. [DOI: 10.1016/j.cca.2018.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nicolini A, Ferrari P, Rossi G. Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer. Adv Exp Med Biol 2015;867:197-225. [PMID: 26530368 DOI: 10.1007/978-94-017-7215-0_13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
11 Randell EW, Yenice S. Delta Checks in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences 2019;56:75-97. [DOI: 10.1080/10408363.2018.1540536] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
12 Lund F, Petersen PH, Pedersen MF, Hassan SOA, Sölétormos G. Criteria to interpret cancer biomarker increments crossing the recommended cut-off compared in a simulation model focusing on false positive signals and tumour detection time. Clinica Chimica Acta 2014;431:192-7. [DOI: 10.1016/j.cca.2014.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Stenman UH. Validating serum markers for monitoring of cancer. Clin Chem 2013;59:4-5. [PMID: 23115053 DOI: 10.1373/clinchem.2012.195222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Lund F, Petersen PH, Fraser CG, Sölétormos G. Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model. Ann Clin Biochem 2015;52:237-44. [DOI: 10.1177/0004563214534636] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
15 Hallworth MJ, Epner PL, Ebert C, Fantz CR, Faye SA, Higgins TN, Kilpatrick ES, Li W, Rana SV, Vanstapel F. Current Evidence and Future Perspectives on the Effective Practice of Patient-Centered Laboratory Medicine. Clinical Chemistry 2015;61:589-99. [DOI: 10.1373/clinchem.2014.232629] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
16 Moreno-campoy EE, Mérida-de la Torre FJ, Martos-crespo F, Plebani M. Identifying risk in the use of tumor markers to improve patient safety. Clinical Chemistry and Laboratory Medicine (CCLM) 2016;54. [DOI: 10.1515/cclm-2015-0760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kristiansen S, Nielsen D, Sölétormos G. Methylated DNA for monitoring tumor growth and regression: how do we get there? Crit Rev Clin Lab Sci 2014;51:149-59. [PMID: 24611610 DOI: 10.3109/10408363.2014.893279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Tölle A, Ratert N, Jung K. miRNA panels as biomarkers for bladder cancer. Biomarkers in Medicine 2014;8:733-46. [DOI: 10.2217/bmm.14.26] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
19 Gulizia MM, Colivicchi F, Ricciardi G, Giampaoli S, Maggioni AP, Averna M, Graziani MS, Ceriotti F, Mugelli A, Rossi F, Medea G, Parretti D, Abrignani MG, Arca M, Perrone Filardi P, Perticone F, Catapano A, Griffo R, Nardi F, Riccio C, Di Lenarda A, Scherillo M, Musacchio N, Panno AV, Zito GB, Campanini M, Bolognese L, Faggiano PM, Musumeci G, Pusineri E, Ciaccio M, Bonora E, Cantelli Forti G, Ruggieri MP, Cricelli C, Romeo F, Ferrari R, Maseri A. ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. Eur Heart J Suppl 2017;19:D3-D54. [PMID: 28751833 DOI: 10.1093/eurheartj/sux029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
20 Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 2015;61:809-20. [PMID: 25882892 DOI: 10.1373/clinchem.2015.239863] [Cited by in Crossref: 91] [Cited by in F6Publishing: 60] [Article Influence: 13.0] [Reference Citation Analysis]
21 Kristiansen S, Jørgensen LM, Guldberg P, Sölétormos G. Aberrantly Methylated DNA as a Biomarker in Breast Cancer. Int J Biol Markers 2013;28:141-50. [DOI: 10.5301/jbm.5000009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
22 Hayes DF. From genome to bedside: Are we lost in translation? The Breast 2013;22:S22-6. [DOI: 10.1016/j.breast.2013.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
23 Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med 2013;5:196cm6. [PMID: 23903752 DOI: 10.1126/scitranslmed.3005950] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 11.0] [Reference Citation Analysis]